UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): October 26, 2022
NURIX THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Delaware | 001-39398 | 27-0838048 | ||
(State or Other Jurisdiction of Incorporation or Organization) | (Commission File Number) | (IRS Employer Identification No.) |
1700 Owens Street, Suite 205 San Francisco, California | 94158 | |
(Address of Principal Executive Offices) | (Zip Code) |
(415) 660-5320
(Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered | ||
Common Stock, $0.001 par value per share | NRIX | Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 | Other Events. |
As previously announced, on October 26, 2022, Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix Therapeutics, Inc. (the “Company”), will make a Keynote Plenary presentation at the 5th Annual Targeted Protein Degradation Summit (the “TPD Summit”). During the Keynote Plenary session, Dr. Sands will present new preliminary clinical data comprised of a case study of a patient with aggressive non-germinal center B-cell diffuse large B cell lymphoma from the Company’s ongoing Phase 1 clinical trial of NX-2127. A copy of Dr. Sands’ presentation material for the TPD Summit is attached as Exhibit 99.1 hereto and is incorporated herein by reference. Also on October 26, 2022, the Company issued the press release attached as Exhibit 99.2 hereto, which is incorporated herein by reference.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
The following exhibits are filed herewith and this list is intended to constitute the exhibit index:
99.1 | Nurix Therapeutics, Inc. presentation dated October 26, 2022. | |
99.2 | Nurix Therapeutics, Inc. press release dated October 26, 2022. | |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
NURIX THERAPEUTICS, INC. | ||||||
Date: October 26, 2022 | By: | /s/ Christine Ring | ||||
Christine Ring, Ph.D., J.D. | ||||||
General Counsel and Secretary |